Bristol Myers, SystImmune post late-stage trial win for breast cancer drug
Source: SeekingAlpha
2026-02-26 07:54:26 ET
More on Bristol-Myers Squibb
- Bristol-Myers: I'm Buying Post Earnings
- Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength
- Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff
- Bristol Myers a new sector perform at RBC Capital Markets
- CDC Deputy Director Ralph Abraham steps down
Read the full article on Seeking Alpha
For further details see:
Bristol Myers, SystImmune post late-stage trial win for breast cancer drug
Bristol-Myers Squibb Company
NASDAQ: BMY
BMY Trading
0.33% G/L:
$59.135 Last:
3,589,652 Volume:
$59.67 Open:
BMY Latest News
March 09, 2026 06:59:00 am
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
BMY Stock Data
$123,325,918,376
2,034,328,000
N/A
1394
N/A
Pharmaceuticals
Healthcare
US
Princeton
